A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors Johnson & Johnson
- 08 Mar 2018 Planned End Date changed from 1 Aug 2018 to 1 Mar 2021.
- 08 Mar 2018 Planned initiation date changed from 29 Jun 2018 to 1 Aug 2018.
- 11 Jan 2018 Planned initiation date changed from 15 Jan 2018 to 29 Jun 2018.